Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
Dana-Farber Cancer Institute
Genmab
Takeda
Celgene
University of Wisconsin, Madison
Celgene
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Centre Antoine Lacassagne
National Institutes of Health Clinical Center (CC)
Universität des Saarlandes
University Hospital Southampton NHS Foundation Trust
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Takeda
National Institutes of Health Clinical Center (CC)
University of Chicago
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Mayo Clinic
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Australasian Leukaemia and Lymphoma Group
University College, London
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
University of Birmingham
University of Nebraska
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Rush University Medical Center
Weill Medical College of Cornell University
Gustave Roussy, Cancer Campus, Grand Paris
National Institutes of Health Clinical Center (CC)
University of Southampton
Seagen Inc.
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health Clinical Center (CC)
SWOG Cancer Research Network
M.D. Anderson Cancer Center
Universität des Saarlandes
Alliance for Clinical Trials in Oncology
Universität des Saarlandes
Universität des Saarlandes
Universität des Saarlandes
European Organisation for Research and Treatment of Cancer - EORTC